C-Path and the European Joint Programme on Rare Diseases to Expand Global Impact and Partnership
PARIS, France and TUCSON, Ariz., U.S., February 1, 2022 — Critical Path Institute (C-Path), an independent global nonprofit organization, and the European Joint Programme on Rare Diseases (EJP RD), an initiative that has received funding from the European Union’s Horizon 2020 research and innovation programme, have announced a collaboration to advance technologies and methodologies that are fit for regulatory purposes to further global rare disease research and drug development.
C-Path has a proven track record in establishing public-private-partnerships that positively impact the process of medical product development in rare diseases. EJP RD promotes integration, efficacy, production and social impact of research in rare diseases. In this context, EJP RD and C-Path have successfully established a collaboration using a shared data model to demonstrate that key datasets from both efforts can be queried simultaneously.
“Collaboration is a foundational principle of success to address unmet needs in medical product development in rare diseases,” said C-Path Chief Science Officer Klaus Romero, M.D., M.S., F.C.P. “As novel approaches are vital to address these unmet needs, our partnership with EJP RD will expand our global capabilities in collaborating for methodologies and technologies to accelerate research with tangible impact for individuals and their families living with rare disease.”
Building on the experience from the past year , both organizations will support the creation of an interoperable global data ecosystem for rare disease to expedite effective development of new therapies. The partnership will benefit patients, regulators, advocacy stakeholders, researchers and industry.
“The cooperation between EJP RD and C-Path not only allows us to bring our unique expertise together, but also sets the foundation for future joint actions in the data, regulatory and clinical methodology space strengthening capacities of the research and development community in EU and on a global scale,” said EJP RD Coordinator Daria Julkowska, Ph.D., Assistant Director, Thematic Institute of Genetics, Genomics & Bioinformatics, INSERM.
Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path’s mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established numerous global consortia that currently include more than 1,600 scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and dozens of pharmaceutical and biotech companies. C-Path U.S. is headquartered in Tucson, Arizona and C-Path, Ltd. EU is headquartered in Dublin, Ireland, with additional staff in multiple other locations. For more information, visit c-path.org and c-path.eu.
About EJP RD
The European Joint Programme on Rare Diseases (EJP RD) is a programme aiming to create an effective rare diseases research ecosystem for progress, innovation and for the benefit of everyone with a rare disease. EJP RD supports rare diseases stakeholders by funding research, bringing together data resources & tools, providing dedicated training courses, and translating high quality research into effective treatments.
For more information, please contact email@example.com.
Critical Path Institute is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) and is 54.2% funded by the FDA/HHS, totaling $13,239,950, and 45.8% funded by non-government source(s), totaling $11,196,634. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.
The European Joint Programme on Rare Diseases is an initiative that has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement N°825575.